Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Squamous Cell Carcinoma of Head and Neck 6Head and Neck Neoplasms 6Lung Neoplasms 4Neoplasm Metastasis 3Melanoma 3Skin Neoplasms 2Recurrence 2Cholangiocarcinoma 2Advanced Solid Tumor 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Squamous NSCLC 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Neoplasms, Squamous Cell 1Neoplasms 1Mouth Neoplasms 1Mesothelioma 1Liver Neoplasms 1Laryngeal Neoplasms 1Laryngeal Diseases 1Klatskin Tumor 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Nonsquamous Non-small Cell Lung Cancer × pembrolizumab × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡